Literature DB >> 24791617

Clear vision through the haze: a practical approach to ground-glass opacity.

Ahmed H El-Sherief1, Matthew D Gilman2, Terrance T Healey3, Rosemary H Tambouret4, Jo-Anne O Shepard2, Gerald F Abbott2, Carol C Wu5.   

Abstract

Ground-glass opacity (GGO) is a common, nonspecific imaging finding on chest computed tomography that may occur in a variety of pulmonary diseases. GGO may be the result of partial filling of alveolar spaces, thickening of the alveolar walls or septal interstitium, or a combination of partial filling of alveolar spaces and thickening of the alveolar walls and septal interstitium at the histopathologic level. Diseases that commonly manifest on chest computed tomography as GGO include pulmonary edema, alveolar hemorrhage, nonspecific interstitial pneumonia, hypersensitivity pneumonitis, and pulmonary alveolar proteinosis. Generating an extensive list of possible causes of GGO in radiologic reports would not be helpful to referring physicians. Preferably, a more concise and focused list of differential diagnostic possibilities may be constructed using a systematic approach to further classify GGO based on morphology, distribution, and ancillary imaging findings, such as the presence of cysts, traction bronchiectasis, and air trapping. Correlation with clinical history, such as the chronicity of symptoms, the patient's immune status, and preexisting medical conditions is vital. By thorough analysis of imaging patterns and consideration of relevant clinical information, the radiologist can generate a succinct and useful imaging differential diagnosis when confronted with the nonspecific finding of GGO.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24791617     DOI: 10.1067/j.cpradiol.2014.01.004

Source DB:  PubMed          Journal:  Curr Probl Diagn Radiol        ISSN: 0363-0188


  8 in total

1.  Correlation between ground-glass opacity on pulmonary CT and the levels of inflammatory cytokines in patients with moderate-to-severe COVID-19 pneumonia.

Authors:  Zubo Wu; Xiaoping Liu; Jie Liu; Feng Zhu; Yali Liu; Yalan Liu; Hua Peng
Journal:  Int J Med Sci       Date:  2021-04-16       Impact factor: 3.738

2.  Clinico- pathologic presentation of hypersensitivity pneumonitis in Egyptian patients: a multidisciplinary study.

Authors:  Dalia Abd El-Kareem; Yosri M Akl; Gina A Nakhla; Ali A Elhindawi; Mahmoud A Eltorky
Journal:  Multidiscip Respir Med       Date:  2017-05-08

Review 3.  [Progressions on Diagnosis and Treatment of Ground-glass Opacity].

Authors:  Yue Zhao; Rui Wang; Haiquan Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-11-20

4.  Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.

Authors:  Y Wu; T Wang; C Guo; D Zhang; X Ge; Z Huang; X Zhou; Y Li; Q Peng; J Li
Journal:  QJM       Date:  2020-08-01

5.  Radiographic findings of SARS-CoV-2 infection.

Authors:  Catherine A Marco; Steven J Repas; Haely Studebaker; Nancy Buderer; Joseph Burkhammer; Jonathan Shecter; Amanda Hinton; J Michael Ballester; John Paul Angeles; Benjamin Kleeman
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-03-03

6.  Predictive value of mutant p53 expression index obtained from nonenhanced computed tomography measurements for assessing invasiveness of ground-glass opacity nodules.

Authors:  Wei Wang; Jian Li; Ransheng Liu; Aixu Zhang; Zhiyong Yuan
Journal:  Onco Targets Ther       Date:  2016-03-14       Impact factor: 4.147

7.  Predominant diffuse ground glass opacity in both lung fields: A case of sarcoidosis with atypical CT findings.

Authors:  Chunmei Ma; Yadong Zhao; Taihua Wu
Journal:  Respir Med Case Rep       Date:  2016-01-22

8.  Rapidly progressing lepidic pulmonary metastases from a treated poorly differentiated hepatocellular carcinoma demonstrating new pathologic features of cholangiocarcinoma: A potential diagnostic pitfall that may mimic pneumonia.

Authors:  Partha Hota; Chandra Dass; Maruti Kumaran; Xiaofeng Zhao; Nirag Jhala; Scott Simpson
Journal:  Radiol Case Rep       Date:  2018-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.